Myriad Genetics downgraded to Underperform at JMP Securities JMP Securities downgraded Myriad Genetics to Underperform from Market Perform after the Centers for Medicare & Medicaid Services said Friday that the BRCA pricing was not a misprint. JMP sees little chance that the prices will revert to the previous level of around $2,900 for code 81211 and set a $15 price target for Myriad shares.
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Myriad Genetics advises prior BRACAnalysis news release be disregarded Myriad Genetics advised that readers should disregard the news release, "Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis" issued April 7 by the company over GlobeNewswire.